Overview

Tirbanibulin for Pediatric Warts

Status:
RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.
Phase:
PHASE4
Details
Lead Sponsor:
The Skin Center Dermatology Group